Prognostic impact of miR-125b and miR-155b and their relationship with MYC and TP53 in diffuse large B-cell lymphoma: cell-of-origin classification matters

被引:0
作者
Neves Filho, Eduardo Henrique Cunha [1 ,4 ]
Zancheta, Stella Barbanti [1 ,2 ]
Silva, Paulo Goberlanio de Barros [2 ]
Burbano, Rommel Mario Rodriguez [3 ]
Rabenhorst, Silvia Helena Barem [1 ]
机构
[1] Univ Fed Ceara, Dept Patol & Med Legal, LABGEM, Fortaleza, Brazil
[2] UNICHRISTUS, Fortaleza, Brazil
[3] Hosp Ophir Loyola, Belem, Brazil
[4] Univ Fed Ceara, Fac Med, Dept Patol & Med Legal, Lab Genet Mol LABGEM, Rua Cel Nunes Melo, 1315, Campus Porangabussu, BR-60183630 Fortaleza, Ceara, Brazil
关键词
diffuse large B-cell lymphoma; miR-125b; miR-155b; MYC; TP53; P53; EXPRESSION; SURVIVAL; MARKER; MICRORNAS; TISSUE; TUMOR; TP53; BCL2;
D O I
10.3960/jslrt.23009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tumoral microRNAs, such as miR-125b and miR-155b, are important gene expression regulators with complex pathogenetic mechanisms. However, their role in DLBCL, especially when cell-of-origin classification is considered, are still to be elucidated. In a series of 139 DLBCL cases considering germinal center (GC) versus nonGC subtypes, we investigated miR-125b and miR-155b expression by in situ hibridization and their association with some immunophenotypic presentations, including MYC, BCL2 and TP53 expression, MYC, BCL2 and BCL6 translocation status, as well as clinicopathological features and outcomes. miR-125b detection was positively correlated to the Ki-67 index (P = 0.035) in the nGC. Considering the GC subgroup, the percentage of miR-125b positive cells was also correlated to either MYC and MYC/BCL2 double expression (P = 0.047 and P = 0.049, respectively). When it comes to nGC patients, miR-155b percentage and intensity, as well as Allred score, were positively correlated to disease progression (P = 0.038, P = 0.057 and P = 0.039, respectively). In a multivariate analysis, GC phenotype was a significant independent factor associated with higher OS (P = 0.007) and, considering the nGC group, although not significant, the expression of TP53, miR-125b and miR-155b seems to be potential prognostic biomarkers in these tumors. This study demonstrated different pathways based on cell-of-origin classification and highlighted different clinical outcomes. miR-125b, miR-155b and TP53 expression may also represent potential prognostic factors in nGC-DLBCL.
引用
收藏
页码:164 / 172
页数:9
相关论文
共 50 条
  • [31] MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway
    Wang, Wei-Ge
    Jiang, Xiang-Nan
    Liu, Ze-Bing
    Zhou, Xiao-Yan
    Li, Xiao-Qiu
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2017, 41 (04) : 541 - 549
  • [32] Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial
    Chiappella, Annalisa
    Diop, Fary
    Agostinelli, Claudio
    Novo, Mattia
    Nassi, Luca
    Evangelista, Andrea
    Ciccone, Giovannino
    Di Rocco, Alice
    Martelli, Maurizio
    Melle, Federica
    Moia, Riccardo
    Motta, Giovanna
    Righi, Simona
    Santambrogio, Elisa
    Tucci, Alessandra
    Balzarotti, Monica
    Ladetto, Marco
    Pileri, Stefano A.
    Gaidano, Gianluca
    Vitolo, Umberto
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (05) : 1184 - 1193
  • [33] TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP
    Liu, Yalu
    Wang, Xiaogan
    Ding, Ning
    Mi, Lan
    Ping, Lingyan
    Jin, Xuan
    Li, Jiao
    Xie, Yan
    Ying, Zhitao
    Liu, Weiping
    Zhang, Chen
    Deng, Lijuan
    Song, Yuqin
    Zhu, Jun
    [J]. BMC CANCER, 2017, 17
  • [34] Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas
    Zlamalikova, Lenka
    Moulis, Mojmir
    Ravcukova, Barbora
    Liskova, Kvetoslava
    Malcikova, Jitka
    Salek, David
    Jarkovsky, Jiri
    Svitakova, Miluse
    Hrabalkova, Renata
    Smarda, Jan
    Smardova, Jana
    [J]. ONCOLOGY REPORTS, 2017, 38 (04) : 2535 - 2542
  • [35] MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma
    Xu, Jie
    Liu, Jing-Lan
    Medeiros, L. Jeffrey
    Huang, Wenting
    Khoury, Joseph D.
    McDonnell, Timothy J.
    Tang, Guilin
    Schlette, Ellen
    Yin, C. Cameron
    Bueso-Ramos, Carlos E.
    Lin, Pei
    Li, Shaoying
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (04) : 336 - 343
  • [36] Preliminary study on decreasing the expression of FOXP3 with miR-155 to inhibit diffuse large B-cell lymphoma
    Zhang, Jincheng
    Wei, Bin
    Hu, Huixian
    Liu, Fanrong
    Tu, Yan
    Zhao, Minzhe
    Wu, Dongmei
    [J]. ONCOLOGY LETTERS, 2017, 14 (02) : 1711 - 1718
  • [37] Changes in non-coding sequences of the TP53 gene in diffuse large B-cell lymphoma
    Voropaeva, E. N.
    Pospelova, T., I
    Voevoda, M., I
    Maksimov, V. N.
    [J]. GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2019, 63 (03): : 239 - 249
  • [38] TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype
    Zainuddin, Norafiza
    Berglund, Mattias
    Wanders, Alkwin
    Ren, Zhi-Ping
    Amini, Rose-Marie
    Lindell, Monica
    Kanduri, Meena
    Roos, Goran
    Rosenquist, Richard
    Enblad, Gunilla
    [J]. LEUKEMIA RESEARCH, 2009, 33 (01) : 60 - 66
  • [39] Frequency, spectrum, and functional significance of TP53 mutations in patients with diffuse large B-cell lymphoma
    E. N. Voropaeva
    T. I. Pospelova
    M. I. Voevoda
    V. N. Maksimov
    [J]. Molecular Biology, 2017, 51 : 53 - 60
  • [40] Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma
    Lin, Pei
    Dickason, Timothy J.
    Fayad, Luis E.
    Lennon, Patrick A.
    Hu, Peter
    Garcia, Mar
    Routbort, Mark J.
    Miranda, Roberto
    Wang, Xumei
    Qiao, Wei
    Medeiros, L. Jeffrey
    [J]. CANCER, 2012, 118 (06) : 1566 - 1573